Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrochlorothiazide is a thiazide diuretic (water pill) used primarily to treat hypertension (high blood pressure) and edema (fluid retention) associated with conditions such as congestive heart failure, liver cirrhosis, kidney disorders including nephrotic syndrome and glomerulonephritis. It works by inhibiting sodium reabsorption in the distal convoluted tubule of the kidney via blockade of the sodium-chloride symporter. This action increases excretion of sodium and water in urine while reducing fluid volume in tissues and blood vessels. The drug was first approved by the FDA in 1959 and is widely prescribed both alone and as part of fixed-dose combination products with other antihypertensive agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrochlorothiazide.